ROS1 gene change. Five drugs are approved to target the abnormal ROS1 protein. Ceritinib (Zykadia) Crizotinib (Xalkori) Entrectinib (Rozlytrek) Lorlatinib (Lorbrena) Repotrectinib (Agtyro ...

According to the American Lung Association, the ROS1 gene mutation occurs in about 1% to 2% of lung cancers and is more common in patients with little to no history of smoking. The AnHeart ...

Zai Lab Limited (NASDAQ:ZLAB) said on Monday that China’s National Medical Products Administration has accepted the label ...

Roche is developing a companion diagnostic in conjunction with Foundation Medicine to develop a companion diagnostic that will help identify people with NTRK and ROS1 gene fusions. Rozlytrek was ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Brian Gormley covers venture capital and healthcare for The Wall Street Journal.